Ratings Mankind Pharma Limited

Equities

MANKIND

INE634S01028

Market Closed - NSE India S.E. Other stock markets 07:40:31 2024-07-09 am EDT			5-day change	1st Jan Change
2,102 ^INR	+1.95%		-1.25%	+6.05%

Jul. 09	Mankind Pharma Reportedly to See Stake Sale Worth INR 7,630 Million through Block Deal	CI
Jul. 05	Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids	RE

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 50% by 2026.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

With an expected P/E ratio at 45.1 and 37.37 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
MANKIND PHARMA LIMITED	+6.05%	9.9B	-
ELI LILLY AND COMPANY	+59.97%	827B	C+
NOVO NORDISK A/S	+38.38%	634B	B
JOHNSON & JOHNSON	-6.18%	350B	C+
MERCK & CO., INC.	+15.61%	319B	B-
ABBVIE INC.	+8.44%	294B	C+
ASTRAZENECA PLC	+12.68%	240B	B+
NOVARTIS AG	+14.40%	221B	B-
ROCHE HOLDING AG	+0.04%	219B	A+
AMGEN INC.	+9.68%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes